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Abstract:
Human acidic fibroblast growth factor 1 (FGF-1) is a potent modulator of cell
survival and exhibits a universal role in various physiological processes. Though potent,
FGF-1 unbound to heparin is known to show a poor thermal stability and a relatively
short in vivo half-life. Much is known about the structure and relation of FGF-1 with
heparin yet there is still unknown information regarding the exact role of heparin in
stabilizing FGF-1. Thus, the aim of this study is to mutate glycine at position 134 to
glutamic acid in wild type FGF1. G134 is located in the heparin binding pocket, thus the
effects of this mutant will provide direct information on the interaction between heparin
and the mutant form of FGF1. Because G134 is in close proximity to residues R136 and
R133, the incorporation of glutamic acid, a negatively charged residue, in the heparin
binding pocket might contribute to the formation of new electrostatic interactions in the
binding pocket that would plausibly affect the binding affinity of FGF1 to heparin. FGF-1
G134E has been characterized using various biophysical methods. Results of the mutant
characterization will be discussed in greater detail.
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Introduction:
I. FGF overview: Human fibroblast growth factors (FGFs) are potent modulators
of cell survival and are well-known universal ligands participating in various
physiological processes (Dubey and Blaber 2005). FGF’s ubiquitous nature are manifest
in their evolutionary history; with all FGFs sharing conserved mechanisms in both
invertebrates and vertebrates (Itoh and Ornitz 2004; Popovici et al. 2005). FGF signaling
begins, for most FGF families, with a signal peptide that destines FGF out of the interior
of the cell and into the extracellular matrix (ECM). However, FGF1, this paper’s protein
of interest, is not secreted through the endoplasmic reticulum—Gogli secretory pathway
with a signal peptide; rather, FGF1 is secreted independently into the ECM (Nickel 2005
and Revest et al. 2000). Once in the ECM, the fate of FGF varies depending on the FGF
family: FGF may be relocated by a carrier protein, or relocation may occur through the
digestion of the ECM. Once relocated, FGFs have the ability to directly affect target cells
(Powers et al. 2000). In the ECM, FGFs bind with high affinity to heparan sulfate
proteoglycans (HSPG) where FGF may carry out cell communication by either autocrine
or paracrine signaling (Suh et al. 2014). Binding of FGF1 to HSPG is crucial, because a
HSPG is required for the tyrosine kinase, FGF receptor (FGFR), to recognize FGF1 as a
signaling peptide (Pineda-Lucena et al. 1996; Stauber et al. 2000; Ornitz and Itoh, 2001;
Eswarakumar et al. 2005). Once the FGF1-HSPG complex binds to the FGFR on the cell
surface, FGF1 may deliver its mitogenic effects (Johnson and Williams 1993;
Schlessinger 2000). FGF1’s mitogenic activity is meditated by a conformational change
in the FGFR, inducing receptor dimerization, ultimately leading to the “beacon” of
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signaling events characteristic of tyrosine kinase receptors (Powers et al. 2000, Ornitz et
al. 1992, Schlessinger et al. 2000 and Yayon et al. 1991).

Figure 1: Cartoon depicting that heparan sulfate proteoglycans (HSPGs) are intimately associated with FGF receptor binding on the cell
surface (Zakrzewska et al 2008).

II. FGFR overview: The FGF receptor is encoded by four genes, FGFR1–
FGFR4, which contain the blueprints for the receptor’s structure: three extracellular
immunoglobulin (Ig) like domains (D1-D3), one single-pass membrane spanning domain,
and the cytoplasmic tyrosine kinase domain (Mohammadi et al. 2005). A defining feature
of the FGFR is called the “acid box”, a serine-rich amino acid sequence in the linker
region between the extracellular D1 and D2 domains (Beenken and Mohammadi 2009).
The acid box and the D1 domain are thought to play a role in receptor autoinhibition
(Wang et al. 1995). In addition, the extracellular D2-D3 domains are responsible for the
FGF1-HSPG complex binding and specificity (Beenken and Mohammadi 2009).
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There are multiple combinations of FGF and FGFR, as most
FGFs can bind to and activate several receptors; and even further
permutations are possible due to several isoforms of the FGFR being in
existence (Zakrzewska et al. 2008; Beenken and Mohammadi 2009).

cell surface

Two isoforms of the FGFR, b and c, are formed by alternate splicing of
cytoplasm

the D3 domain of the FGFR 1-3 transcript. These isoforms have
different FGF binding specificities, with the b and c isoforms being
epithelial and mesenchymal, respectively (Johnson et al. 1991).
Interestingly, all FGF family members bind to either epithelial or
mesenchymal FGFRs but FGF1 has the ability to activate both
splice isoforms of the FGFR (Beenken and Mohammadi 2009).

Figure 2: Cartoon depicting the FGF
receptor (FGFR) which consists of: three
extracellular immunoglobulin (Ig) like
domains (D1-D3), the acid box, one singlepass membrane spanning domain, and the
cytoplasmic tyrosine kinase domain
(Lemmon and Schlessinger, 2010).

III. Ligand-receptor interaction and the triggering of downstream events:
A. Receptor Dimerization: After the binding of the FGF1-HSPG complex to the
FGFR, autophosphorylation of the FGFR occurs. Looking at the big picture,
autophosphorylation of the tyrosines, in the cytoplasmic tyrosine kinase domain, marks a
major event for FGF1 signaling. There is a boost in activity of the receptor kinase, and
the recruitment and activation of downstream signaling molecules as they bind to the
phosphotyrosines of the FGFR (Eswarakumar et al. 2005). Importantly,
autophosphorylation of the receptor serves as an “on-switch” for many broad reaching
cellular processes like that of proliferation, differentiation, and migration (Zakrzewska et
al. 2008).
B. Receptor Activation: Specifically, autophosphorylation occurs when the FGFR
dimerizes allowing the cytoplasmic kinases domains to “crossphosphorylate”, or

7

transphosphorylate, on A loop tyrosines which become activated. Phosphorylation of
residues on A loop is followed with phosphorylation of the tyrosines in the C tail, which
are kinase insert and juxtamembrane regions (Mohammadi et al. 1996). A
phosphorylation at tyrosine 766 (Y766) in the C tail on the FGFR is necessary for the
binding and activation of one of the main intracellular downstream signaling molecules—
phospholipase C (PLC) γ. Phosphorylated Y766 creates a binding site for the interaction
of PLCγ’s SH2 domain (Beenken and Mohammadi 2009). After the activation of PLCγ,
downstream messengers like IP3 and DAG are activated leading to an increase in
cytoplasmic calcium levels and activation of protein kinase C (PKC).

Figure 3: Cartoon showing the four main signaling pathways triggered by the interaction of FGF-FGFR
(labeled 1-4): 1, Janus kinase/signal transducer and activator of transcription; 2, phosphoinositide
phospholipase C, 3, phosphatidylinositol 3-kinase; and 4, mitogen-activated protein kinase (Lanner and
Rossant 2010).

Another important downstream substrate of the FGFR is FGFR substrate 2
(FRS2). In contrast to PLCγ, FRS2 does not bind to the phosphotyrosine domain; rather
FRS2 binds to the juxtamembrane region of the FGFR. The constitutive association of
8

FRS2 to the FGFR receptor leads to FRS2 phosphorylation, triggering the activation of
the Ras and PI3 kinase–Akt signaling pathways (Dailey et al. 2005).
C. Receptor endocytosis: Signaling from the FGFR is not limited only to the
membrane, but the FGFR also exhibits activity in the cytosol and nucleus of cells. This
activity of the FGFR out of the cell membrane is made possible through the endocytosis
of the activated FGF–FGFR complexes and also through sources of ligand within the cell
(Wiedlocha and Sorensen 2004). The FGF–FGFR complexes are endocytosed by the
clathrin-mediated pathway; however, other mechanisms for the internalization of FGF–
FGFR have been postulated (Marchese et al. 1998, Citores et al. 1999, and Citores et al.
2001).
IV. FGF’s interaction with heparin: Though FGF1 is potent, apart from HSPG,
FGF1 is known for having poor thermal stability and a relatively short in vivo half-life
(Culajay et al. 2000). The 154 amino acids of FGF1 are oriented so that regions important
for folding are distributed within the protein with regions associated with the function
i.e., heparin binding affinity and receptor binding affinity that fold late in the folding
pathway (Longo et al. 2012). Most known members of the FGF family contain a HSPG
binding pocket, where the binding of FGF1 to heparan sulfate proteoglycans protects
FGF1—shielding it against proteases and thermal denaturation—in addition to aiding
FGF1 to bind to and activate its FGFR. (Rapraeger et al. 1991 & Yayon et al. 1991). The
structure of HSPG can be simplified as decasaccharides consisting of a helix arranged by
repeating α-1-4 linkage disaccharide units of D-glucos-amine and L-iduronic acid
(Schlessinger et al. 2000). HSPGs are referred to as “sugar” proteins (glycoproteins) all
of which contain one or more covalently attached heparan sulfate chain and a core protein
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(Esko et al. 2009). The core protein can either traverse the cell membrane or it can be
anchored to the membrane by a glycosylphosphatidylinositol (Zakrzewska et al. 2008).
Heparin is a highly sulfated form of heparan sulfate, therefore negatively charged, and is
found at the cell surface and in the extracellular matrix where it interacts with FGF1 and
numerous other ligands (Sarrazin et al. 2011). HSPGs act as a template to bring together
the FGF1 ligand and receptor by simultaneous binding both FGF and FGFR (Sarrazin et
al. 2011). This synchronous binding helps stabilize the interactions between FGF1 and its
FGFR (Hacker et al. 2005). Also noteworthy, HSPGs enable FGF to bind to several
FGFRs (Zakrzewska et al. 2008). In contrast to the FGFR, HSPGs are in greater
abundance and form oligomeric complexes with FGF1 (Zakrzewska et al. 2008). Due to
FGF1’s need to interact with heparin for FGFR activation, FGF1 displays what is called a
“dual-receptor model” of binding. Though FGF1 interacts with relative high affinity to
HSPGs, the dual receptor model depends on FGF interacting with both a “low affinity
receptor”, HSPG, and “high affinity receptor”, FGFR (Rapraeger et al. 1991, Yayon et al.
1991, Spivak-Kroizman et al. 1994, Klagsbrun et al. 1991, and Ornitz et al. 1992).

Figure 4: Image showing the chemical structure of the repeating
(glucosamine — L-iduronic acid) units of heparin. (Ou et al. 2015)

The HSPG binding site is located inside the core of FGF which is made up of the
β1–β2 loop and parts of the region across β10 and β12 (Beenken & Mohammadi 2009).
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Because FGF1 binds to heparin with high affinity, immobilized heparin affinity
chromatographic resins are used for purification of FGF1 and many other growth factors.
As mentioned above, HSPGs are required if FGF1 is to activate the FGFR and induce its
signaling cascade. Therefore, HSPG is characterized as a “coreceptor” because its
function is to bind to FGF1 (and other ligands) to form complexes that may trigger a
conformational change of the ligand and/or the receptor. Because heparin is sulfated it
forms electrostatic interactions with FGF. Particularly, some of the positive residues of
FGF1 that interact with heparin are K126, K127, R133 and R136 to name a few.

Figure 5: PyMOL image showing heparin and FGF-1 bound with a
selection of some labeled amino acid residues that participate in the
electrostatic interactions with heparin in the FGF1 binding pocket.
Heparin is represented by the primarily light blue stick model in the
top section of the cartoon.

V. FGF Family member’s overview: To date, there are 18 known mammalian
FGFs classified into 6 subfamilies (1, 4, 7, 8, 9, and 19) based on sequence homology and
evolutionary history (Itoh and Ornitz, D 2004). FGF1 and FGF2 are grouped into the
FGF1 subfamily; FGF4, FGF5, and FGF6 are grouped into the FGF4 subfamily; FGF3,
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FGF7, FGF10 and FGF22 are grouped into the FGF7 subfamily; FGF8, FGF17, and
FGF18 are grouped into the FGF8 subfamily; FGF9, FGF16, and FGF20 are grouped into
the FGF9 subfamily, and FGF19, FGF21, and FGF23 are grouped into the FGF19
subfamily.
There is a seventh FGF subfamily, the FGF11 subfamily, consisting of FGF
members FGF11-FGF14. However, it was discovered that the FGF11 subfamily do not
activate FGFRs, even though they display high sequence homology with the FGF family
(Olsen et al. 2003). Therefore, the FGF11 subfamily members are generally no longer
considered members of the FGF family (Olsen et al. 2003).

Figure 6: Evolutionary relationships between the
twenty-two identified FGFs in mice. The “Fgf subfamily”
is also referred to as the FGF 11 subfamily, which do
not activate FGF receptors. The “hFgf subfamily” is
sometimes referred to as the FGF19 subfamily. Note:
FGF15 represents the mouse ortholog of human FGF19
(Itoh and Ornitz 2008).

All FGF family members share a high affinity for heparin and heparan-like
glycosaminoglycans (Burgess and Maciag 1989). In addition, all FGFs also share a
homologous central core of 120-130 amino amino acids arranged into 12 antiparallel βstrands (β1-β12) with different amino and carboxyl terminals (Beenken and Mohammadi
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2009). This difference in amino and carboxyl tails is what accounts for the different
biological effects of the FGF family members (Mohammadi et al. 2005). The acronym of
FGF, “fibroblast growth factor”, may be misleading in implying that each FGF stimulates
fibroblasts; this is not the case—FGF7 does not stimulate fibroblasts (Powers et al. 2000).
Rather, the FGF initials are meant to show that each factor belongs to the same family,
because they all share common structure—with the exception of FGF11-FGF14 not being
regarded as FGF family members, as mentioned above.
FGFs regulate an eclectic group of developmental processes. The first five
subfamilies of FGF, which includes FGF1, are paracrine factors and have roles in tissue
patterning and the creation of organs in development (Beenken and Mohammadi 2009).
In adults, members of the FGF19 subfamily haven been shown to act in an endocrine
manner by regulating cholesterol, bile acid, glucose, vitamin D, and phosphate
homeostasis (Fu et al 2004, Kharitonenkov et al. 2005, Razzaque and Lanske 2007, and
Tomlinson et al. 2002). The following contains tables, addressing each mammalian FGF
subfamily and their individual members.
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FGF Ligand:

FGF1, this
paper’s protein
of interest.

FGF2

Molecular
Weight
in kDa:
8

16

8

18
22.5
23.1
24.2

Functional Activity:

Refs:

Physiological Role: The physiological role of FGF1 is remains uncertain,
although it is thought to play some part in the maintenance of vascular
tone1,2*. FGF1 Knockout: Interestingly, FGF1 knockout mice exhibit no
apparent complications3. Medical Applications: FGF1 has been shown to:
regenerate transected spinal cords in rats4, improve collateral artery growth
and capillary proliferation5, treat insulin resistance and type 2 diabetes in
mice6, and in combination with nerve grafts, FGF1 has partly restored
movement to the paraplegic7.
Physiological Role: Like FGF1, the physiological role of FGF2 is still
unsure; in addition, FGF2 is thought to play some role in the maintenance of
vascular tone1,2*. FGF2 Knockout: like FGF1, FGF2 knockout mice exhibit
no apparent complications3. Medical Applications: FGF2 is the most studied
FGF, where it has therapeutic potential for cardiovascular disease and
prostate and renal cancer4,5,6,7.

1

Cuevas, et al. 1991, 2Cuevas
et 1996, 3Miller et al. 2000,
4
Cheng et al. 1996,
5
Schumacher et al. 1998,
6
Suh et al. 2014, 7Cheng et
al. 2004, and 8Blaber 1996.

1

Cuevas, et al. 1991, 2Cuevas
et 1996, 3Miller et al. 2000,
4
Unger et al. 2000, 5Laham
et al. 1999, 6Simons et al.
2002, and, 7Sellke et al.
1998, and 8Florkiewicz and
Sommer 1989.

Table 1: The FGF1 subfamily — Molecular weights and general functional activity,

FGF Ligand:

Molecular
Weight
in kDa:
5

FGF4
22

2,3,4

FGF5
32-38

4

FGF6
25

Functional Activity:

Refs:

Physiological Role: FGF4 functions in the formation heart valve leaflets1 and the
development of limbs2. FGF4 Knockout: FGF4 knockout mice are lethal due to
FGF4’s involvement in trophoblast proliferation3. Medical Applications: FGF4 has
been administered as means of gene therapy for stable angina in women4.

1

Physiological Role: FGF5 serves as a negative regulator of a step in the hair
follicle growth cycle1. FGF5 Knockout: FGF5 knockout mice have very long hair,
without any other complications1. Medical Applications: There is a potential to
create FGF5 inhibitors to support hair growth1.
Physiological Role: FGF6 plays a role in the development of muscle tissue1. FGF6
Knockout: FGF6 knockout mice displayed damaged muscle regeneration where
they showed substantial thickening and scarring of connective tissue after a freezecrush injury2. Medical Applications: As of now, there are no current therapeutic
applications of FGF63.

Sugi et al. 2003, 2Sun
et al. 2002, 3Feldman
et al. 1995, 4Henry et
al. 2007, and 5Delli
Bovi et al. 1987.
1
Hebert et al. 1994,
2
Goldfarb, M. et al.
1991, 3Zhan et al.
1988, and 4Bates et al.
1991.
1
Armand et al. 2006,
2
Floss et al. 1997,
3
Beenken and
Mohammadi 2009,
and 4Coulier et al.
1991.

Table 2: The FGF4 subfamily — Molecular weights and general functional activity.

14

FGF Ligand:

Molecular
Weight
in kDa:
3,4

FGF3
28-32

7,8

FGF7

28

6

FGF10
30

FGF22

Functional Activity:

Refs:

Physiological Role: FGF3 serves a very specific role for inner ear development1.
FGF3 Knockout: FGF3 human knockouts showed deafness in addition to a few
dental defects1. Medical Applications: As of now, there are no current therapeutic
applications of FGF32.

1

Physiological Role: FGF7 serves aids morphogenesis1. FGF7 is expressed
specifically in mesenchyme tissue, where FGF7 concentrations are increased
dramatically (150-fold) in skin after skin injury2. In addition, FGF7 levels increase
after bladder and kidney injury3,4. FGF7 Knockout: FGF7 knockout mice show
minor abnormalities like matted hair5, and have 30% fewer nephrons compared to
control mice1. Medical Applications: FGF7 is used as Palifermin, an FDA
approved, N-terminally truncated form of FGF7 with increased stability.
Palifermin is used for the treatment of chemoradiation-induced mucositis in
patients undergoing bone marrow transplantation6.
Physiological Role: FGF10 serves in branching morphogenesis1. It is a presynaptic
organizer that serves in vesicle clustering and neurite branching2. FGF10
Knockout: FGF10 knockout mice do not develop limbs and lung structures1.
Medical Applications: FGF10 and FGF7 are thought to play a part in the
pathogenesis of prostate cancer by promoting epithelial cell proliferation3,4.
However, there are no current therapeutic applications of FGF105.

Physiological Role: FGF22 is a presynaptic organizer that serves in vesicle
clustering and neurite branching1. FGF22 Knockout: FGF22 currently has no
..
knock mice model2. Medical Applications: There are no current therapeutic
applications of FGF102.
Table 3: The FGF7 subfamily — Molecular weights and general functional activity.

Tekin et al. 2007,
Beenken and
Mohammadi 2009,
3
Brookes et al. 1989,
and 4Antoine et al.
1997.
1
Qiao et al. 1999,
2
Werner et al. 1992,
3
Baskin et al. 1997.
4
Ichimura et al. 1996,
5
Guo et al. 1996,
6
Spielberger et al.
2004, 7Rubin et al.
1989, 8Werner 1998
2

1

Kato and Sekine
1999, 2Umemori et al.
2004, 3Thomson and
Cunha 1999, 4Yan et
al. 1992, 5Beenken and
Mohammadi 2009,
and 6Beer et al. 1997.
1
Umemori et al. 2004,
2
Beenken and
Mohammadi 2009
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FGF Ligand:

Molecular
Weight
in kDa:
5,6

FGF8
28-32

FGF17

Refs:

Physiological Role: FGF8 plays a role in brain, limb, ear, and eye development1.
FGF8 Knockout: FGF8 knockout mice are not able to undergo gastrulation2 and is
therefore lethal. Medical Applications: Loss-of-function mutations result in an
altered FGFR1c binding or cause Kallmann’s syndrome3. However, there are no
current therapeutic applications of FGF84.

1

3,4

Physiological Role: FGF17 is involved in cerebral and cerebellar development1.
FGF17 Knockout: FGF17 knockout mice show abnormalities in the cerebrum and
cerebellum1. Medical Applications: As of now, there are no current therapeutic
applications of FGF172.

3,4

Physiological Role: FGF18 is involved in bone development1,2. FGF18 Knockout:
FGF18 knockout mice express less osteogenic markers and have delayed longbone ossification1,2. Medical Applications: Recombinant FGF18 has anabolic
abilities on cartilage3,4.

25

FGF18

Functional Activity:

31

O’Leary et al. 2007,
Meyers et al. 1998,
3
Falardeau et al. 2008,
4
Beenken and
Mohammadi 2009,
5
MacArthur et al.
1995, and 6Gemel et
al. 1996.
1
Xu et al. 2000,
2
Beenken and
Mohammadi 2009,
3
Xu et al. 1999, and
4
Hoshikawa et al.
1998.
1
Liu et al. 2002,
2
Ohbayashi et al.
2002, 3Ellsworth et al.
2002, 4Moore et al.
2005.
2

Table 4: The FGF8 subfamily — Molecular weights and general functional activity.

FGF Ligand:

Molecular
Weight
in kDa:

FGF9

Functional Activity:

Refs:

4,5

Physiological Role: FGF9 functions in utero in gonadal development and
organogenesis1,2.
FGF9 Knockout: FGF9 knockout mice display male-to-female sex reversal in
addition to lung hypoplasia causing postnatal death1.
Medical Applications: There are currently no therapeutic applications for FGF93.

1

3,4

Physiological Role: FGF16 plays a role in heart development1.
FGF16 Knockout: FGF16 knockout mice have substantial cardiac defects and are
embryonic lethal1.
Medical Applications: There are currently no therapeutic applications for FGF162.

30

FGF16
26

3

FGF20
23

Physiological Role: FGF20 is a neurotrophic factor1.
FGF20 Knockout: There is currently no FGF20 knockout model2.
Medical Applications: Currently, FGF20 is being explored for applications in
Parkinson’s disease1.

Colvin, Green, and et
al. 2001, 2Colvin,
White, and et al. 2001,
3
Beenken and
Mohammadi 2009,
4
Miyakawa et al. 1999,
and 5Naruo et al. 1993.
1
Lu et al. 2008,
2
Beenken and
Mohammadi 2009,
3
Konishi et al. 2000,
and 4Miyake et al.
1998.
1
Ohmachi et al. 2003,
2
Beenken and
Mohammadi 2009,
and 3Kirikoshi et al.
2000.

Table 5: The FGF9 subfamily — Molecular weights and general functional activity.

16

FGF Ligand:

Functional Activity:

Refs:

FGF19

Physiological Role: FGF19, an endocrine FGF, is involved in bile acid
homeostasis, lipolysis, and gall bladder filling1,2,3,4,5,6
FGF19 Knockout: Display an increased bile acid bool7.
Medical Applications: There is the potential for recombinant FGF19 to be used in
treating diabetes1,2,4,5.

1

FGF21

Physiological Role: FGF221, an endocrine FGF, is involved in the fasting
response, glucose homeostasis, lipolysis, and lipogenesis1,2,3
FGF21 Knockout: There is currently no FGF21 knockout model3.
Medical Applications: Like FGF19, recombinant FGF21 has the potential for use
in diabetes1,2,3.
Physiological Role: FGF23, and endocrine FGF, is involved in phosphate
homeostasis and vitamin D homeostasis1,2,3,4,5
FGF23 Knockout: FGF23 knockout mice display hyperphosphataemia,
hypoglycaemia, and Immature sexual organs2,6.
Medical Applications: Currently anti-FGF23 antibodies are being used in
hypophosphataemia4,5

FGF23

Fu et al. 2004,
Tomlinson et al.
2002, 3Xie et al. 1999,
4
Holt et al. 2003,
5
Lundasen et al. 2006,
6
Choi et al. 2006,
7
Inagaki et al. 2005
1
Kharitonenkov et al.
2005, 2Nishimura et al.
2000, 3Beenken and
Mohammadi 2009
2

1

Yamashita et al.
2000, 2Sitara et al.
2004, 3Beenken and
Mohammadi 2009,
4
Aono et al. 2003,
5
Yamazaki et al. 2008,
6
Shimada et al. 2004

Table 6: The FGF19 subfamily— Molecular weights and general functional activity..

VI. Significance and Design of the G134E Mutation: FGF1, this paper’s protein
of interest, is a 16-kDa, made of 12 antiparallel β-strands forming a β-barrel – lacking in
disulfide bonds (Blaber 1996; Zhu et al. 1991; Stauber 2000; Chi et al. 2001; Ornitz and
Itoh 2001). FGF1 possesses incredible therapeutic potential (see table 1 for some
examples). The role of FGF1 in human pathology is well studied—where deviant
signaling of FGF1 is involved in the pathogenesis of cancer (Ornitz and Itoh 2001;
Stauber et al. 2000). In addition, elevated levels of FGF in cancer cells have been shown
to be a culprit for the ability of cancer cells to evade chemotherapy treatment (Song et al.
2000). Even more, FGF-1 is already being utilized to promote wound repair and
angiogenesis (Thompson et al. 1994; Beenken and Mohammadi 2009). Because of
FGF1’s broad therapeutic potential, the use of recombinant proteins like FGF is a
promising therapeutic approach (Zakrzewska 2008). Previous point mutations of FGF1
17

have shown to increase thermal stability, reduce proteolytic degradation, prolong and
increase mitogenic properties, and increase FGF1’s half-life (Zakrzewska 2008).
In this study, a single point mutation was introduced at the 134th amino acid
position of glycine (Gly/G) to alter the glycine residue into glutamic acid (Glu/E). The
overall aim of this group is to create an FGF1 that can be incorporated into wound
healing cosmetics. This FGF1 must have increased resistance to proteolytic degradation,
and an increased half-life to survive not only in the cosmetic agent but also when it is
introduced in vivo (Zorrilla et al. 2010). The engineered mutant of this paper, G134E,
incorporated glutamic acid, an amino acid that is known to be polar and negatively
charged at physiological pH.

G134E

Figure 7: Chemical structures of glycine (left) and glutamic acid (right). The mutant FGF1, G134E, incorporated
glutamic acid at the 134th amino acid position, replacing glycine.

We hypothesize that incorporation of glutamic acid for the nonpolar and uncharged glycine residue will disrupt the electrostatic interactions and cause a decrease in
G134E-FGF1’s affinity for heparin. With a newly incorporated long and negatively
charged side chain containing carboxyl group protruding from the protein backbone, the
negatively charged heparin molecule might be repelled from G134E-FGF1. Proteolytic
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enzymes, like thrombin, are known to cleave FGF1 when bound to heparin so
discouraging FGF1 to heparin may ultimately achieve the goal of increased proteolytic
stability. We also predict that the thermodynamic stability of FGF1 probably would
decrease by the neutralization of positive charged amino acid residues in the vicinity.
Though the thermodynamic stability may decrease with the G134E point mutation, the
incorporation of other point mutations combined with this mutant may discourage
heparin binding and increase thermodynamic stability. Expression of the G134E mutant
in addition to biophysical characterization experiments were completed to explore the
effects of this mutation.

R136

P135

R133

T137
G134

W121

Figure 8: Microenvironment of residues in the heparin binding pocket proximal to the mutation site of G134.
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Experimental Methods:
The equipment and materials used for this study were of high-quality laboratory
grade. For all prepared solutions, double distilled water (ddH2O) was used. All assays
were performed with protein in an environment with 7.2 pH and 10mM phosphate buffer
(PB) with a specified amount of sodium chloride (NaCl). In samples that included
heparin, 10x the amount of heparin was used for the given protein concentration unless
otherwise specified. For all sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) analyses reagents were purchased form VWR. All trichloroacetic acid
preparations (TCA) were performed according to the protocol on protein samples before
running SDS-PAGE analysis.

Bacterial Transformation:
A plasmid containing the G134E mutation was created by site-directed
mutagenesis before the initiation of this study. 1µL of the G134E plasmid was inoculated
in 50µL of BL21 (DE3) super competent E. coli cells then was set on ice for 30 minutes.
BL21 (DE3) super competent E. coli cells was this lab’s cell-line choice due to their lack
of proteolytic enzymes that would degrade G134E and also a show a high efficiency of
transformation. The BL21 (DE3) super competent E. coli cells containing the plasmid
were placed in a 42ºC water bath for 45 seconds to uptake the plasmid and then were
immediately placed on ice for 3 minutes. After the bacterial cells’ uptake of the G134E
plasmid, 800µL of sterile lysogeny broth (LB), a nutrient rich medium, was added to the
cells. This solution was then incubated in a shaker at 250rpm for 45 minutes at 37ºC. A
100µL sample of bacterial cells containing plasmid were uniformly spread on an agar
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plate containing the antibiotic ampicillin (Amp). Ampicillin was selected because the
plasmid utilized in this study has genes that confer the resistance to Amp; consequently,
only the BL21 (DE3) super competent E. coli cells containing plasmid were able to
survive. The agar plate containing the antibiotic ampicillin (Amp) and bacterial cells
were stored upside-down in a 37ºC incubator for 14 hours.

Overexpression of G134E-FGF1:
Small scale expression was completed and checked by SDS-PAGE to verify the
G134E-FGF1 mutant was present. Then glycerol stocks of G134E were prepared in the
Kumar lab prior to this study and stored in a -80ºC freezer. A 1mL glycerol stock was
then taken from the -80ºC freezer and was added to 150 mL of sterile autoclaved LB
media which was allowed to reach room temperature; in addition, 150µL of Amp was
added to the solution. The solution was incubated in a 37ºC shaker at 180rpm for 14
hours. After the 14-hour period, 500µL of Amp was added to six 2L flasks that contained
500mL of LB. An overnight starter culture was pre-grown and 25mL of the pre-grown
starter culture was added to each 2L flask. These six 2L flasks were then incubated at
250rpm at 37ºC (for about 2 hours) until the optical density of the medium reached 0.40.6. After the 6 flasks reached the 0.4-0.6 OD window they were then induced with
500mL of 1M Isopropyl β-D-1-thiogalactopyranoside (IPTG), a chemically analogous
mimic of allolactose. Because IPTG is chemically similar to allolactose, IPTG triggers
expression of the lac operon. Lac operon induction is of particular importance because
our introduced G134E containing plasmid inserts its genetic information downstream and
in close proximity of the lac operon. Therefore, IPTG induces the expression of G134E-
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FGF1 in the BL21 (DE3) super competent E. coli cells. OD was then checked at an
absorbance wavelength of 600nm using UV-vis spectroscopy. The contents of the six 2L
flasks were then divided among centrifuge tubes and were centrifuged at 6,000rpm for 15
minutes. Immediately after centrifugation the supernatant was discarded to prevent pellet
and supernatant re-mixing and the pellets were resuspended in 1xPBS pH 7.2 buffer.
After the pellets were resuspended in PBS buffer, they were then aliquoted into 50mL
flacon tubes and centrifuged one last time for 15 minutes at 6,000rpm. Immediately after
centrifugation the supernatants were discarded and the pellets were stored in a -20ºC
freezer for future use.

Purification of G134E-FGF1:
To purify G134E-FGF1, an affinity chromatographic heparin-Sepharose column
(~20ml bed capacity) was used. The bacterial pellets were removed from the -20ºC
freezer then thawed. The pellets containing the G134E-FGF1 protein were resuspended in
1xPBS pH 7.2 buffer containing 10mM NaCl and were then ultrasonicated while on ice
for 3 sets of 20 cycles of alternating 10 second pulses/10 seconds resting periods with a
power of 15 watts output. In addition, after each set of sonication 2 minutes of rest was
given to the solution to allow it to cool. The sonicated solution containing the lysed
bacterial cells were then centrifuged at 19,000rpm for 20 minutes. The clear supernatant
containing G134E-FGF1 was immediately separated from from the pellet and loaded
onto the pre-equilibrated heparin-Sepharose column with 10mM NaCl containing 10mM
PB. After the supernatant was equilibrated on the heparin-Sepharose column (for 30
minutes) a salt gradient flow-through wash of 10mM PB and 100mM NaCl was passed
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through the column. Next, washes of 500mM NaCl containing 10mM PB, 800mM NaCl
containing 10mM PB, and 1500mM NaCl containing 10mM PB were used to wash
proteins from the heparin-Sepharose column, with pure G134E-FGF1 eluting at 1500mM
NaCl containing 10mM PB. The 1500mM NaCl solution passed through the column
containing G134E was then dialyzed in dialysis tubing with a molecular weight cutoff of
3,500kDa. The last step was concentrating down pure G134E in a Millipore Ultra-15
centrifugal filter concentrator to achieve a final concentration of 1.5mg/mL then storing it
in a -20ºC freezer.

Limited Proteolytic Trypsin Digestion:
To compare the differences in resistance to proteolytic degradation of wild-type
FGF1 (wtFGF1) to G134E-FGF1 limited proteolytic trypsin digestion was used as a
probe with both proteins, wtFGF1 and G134E, in the presence and absence of heparin.
The proteolytic degradation of wtFGF1 and G134E by trypsin was performed in a water
bath at 37ºC where trichloroacetic acid (TCA) was added to reaction mixtures to
terminate the trypsin enzymatic activity. Two separate reaction mixtures for both wtFGF
and G134E were prepared using 1mL of 0.005mg/mL solution of trypsin purified from a
bovine pancreas along with 0.5mg/mL protein in 100mM NaCl containing 10mM PB.
Two additional reaction mixtures were created (giving 4 total reaction mixtures) which
mimicked the prior reaction mixtures but also contained 0.05mg/mL concentrated
heparin. Immediately after all reaction mixtures were made, 100μL of each reaction
mixture was taken from each sample and put on ice and 10μL of TCA was added to stop
the reaction. This now 110μL solution represented the time zero sample with no (or
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negligible) trypsin digestion. The reaction mixtures then incubated in the hot water bath
for 5 minute intervals where at the end of each 5-minute period 100μL of the reaction
mixture was removed, put on ice, and the reaction was halted with 10μL of TCA. The
prior step was repeated for 45 minutes with 5 minute interval until all the reaction
mixtures for each sample were depleted. All the samples, representing varying levels of
trypsin digestion over time, were then processed using established TCA protein
precipitation procedure. Each sample was analyzed for the magnitude of trypsin digestion
using SDS-PAGE and densitometric scanning analysis.

Thermal Denaturation of G134E-FGF1:
To assess the changes in thermodynamic stability of the G134E-FGF1 compared
wtFGF1 a thermal denaturation analysis was conducted on a Jasco 1500
spectropolarimeter using a 31.25μM protein concentration in 10mM NaCl containing
10mM PB. Data obtained was subjected to smoothing function available from the
manufacturer. Appropriate blank subtractions were carried out. The absorbance
wavelength of 228nm was measured from the spectra and the values were plotted against
temperature.

Far-UV Circular Dichroism (CD) Spectroscopy of G134E-FGF1:
Using a Jasco 1500 spectropolarimeter data was collected on 0.5mg/mL samples
of wtFGF1 and G134E FGF1 with and without heparin. 100µL of the solution samples
were added to a 0.2mm path-length quartz cell. The Jasco 1500 spectropolarimeter was
set to a wavelength range of 190-250nm at a 50nm/min scan speed and was loaded with
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the quartz cell containing protein samples. The data was averaged across 3 scans,
smoothed, and the buffer signal was subtracted out all using the JASCO spectra analysis
software. The procedure was also completed for with-heparin samples, with the exception
of the solution mixture that contained a 1:10 protein to heparin ratio. To account for the
excess heparin signal for the solutions in the presence of heparin, the heparin signal was
subtracted out of the data.

8-Anilinonaphthalene-1-sulfonic acid (ANS) Binding Assay:
To examine any changes in three-dimensional structure resulting from the
exposure of interior hydrophobic residues that the G134E mutant may display, ANS
binding assay was used to compare wtFGF1 and G134E-FGF1 in the presence and
absence of heparin. The ANS assay was performed using a Hitachi F-2500
spectrofluorometer at an excitation wavelength of 380nm and an emission wavelength
range of 450-600nm. A stock solution of ANS was made so that for every 1µL addition
of the stock ANS the protein sample would increase the ANS concentration by 20µM.
The protein samples were then diluted to a 15μM concentration. Next an initial recording
of relative fluorescence intensity (RFI) was taken at the fluorescent wavelength of ANS,
500nm. ANS was then added to the protein sample in 1µL increments and the RFI was
recorded for 20 measurements until a final concentration of 400µM ANS was achieved.

Intrinsic Fluorescence Spectroscopy of G134E-FGF1:
To investigate changes in the three-dimensional structure of the G134E mutant
compared to wtFGF1 both in the presence and absence of heparin intrinsic fluoresce
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spectroscopy was used. Samples of 0.1mg/mL of the respected protein in 100mM NaCl
containing 10mM PB were prepared. The samples were then excited at a wavelength of
280nm and data was obtained from the range of 300-450nm to see if the intrinsic
fluorescence of tyrosine (308nm) and tryptophan (350nm) were altered for the mutant
compared to the wild type.

Isothermal Titration Calorimetry (ITC) of G134E-FGF1:
To measure changes in G134E’s affinity to heparin compared to the wild type
ITC was performed on a MicroCal ITC200. Solutions of 500μL containing 0.05mM
G134E-FGF1 in PB buffer and 200μL of 0.5mM heparin in PB buffer were prepared. The
data gathered was fitted with one set of sites binding model available on Origin software.
In addition, excess heparin was subtracted and the binding affinity was determined by the
dissociation constant (Kd).

Bioactivity Assay:
To understand the effects of the G134E mutation on FGF1’s ability to carry out
cellular proliferation, two 50μL samples of 1mg/mL, one for both wtFGF1 and G134E,
were prepared in 100mM NaCl containing PB. The bioactivity assay used NIH/3T3 cells
with increasing concentrations of protein up to 3nM to measure cellular proliferation for
the wild type and G134E-FGF1.
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Results and Discussion:
Isolation of G134E-FGF1 on heparin-Sepharose affinity chromatography:
To perform the biophysical characterization of the G134E mutant, G134E-FGF1
BL21-DE3 cells were transformed with pET20b-G134E-FGF1 mutant plasmid. After
transformation, the bacterial cells housing the G134E mutated protein were then
overexpressed in a nutrient rich LB medium. Successful expression of the G134E mutant
was then verified using 15% SDS-PAGE analysis.
After generating the G134E mutant, pure G134E-FGF1 was isolated on the
heparin-Sepharose column using a phosphate buffer/NaCl salt gradient of increasing
NaCl concentrations from: 500mM NaCl, 800mM NaCl, and 1500mM NaCl with
purified FGF-1 eluting at 1500mM NaCl. Because of FGF1’s characteristic affinity to
heparin, other cellular proteins and cell contents were washed from the heparinSepharose column at the low salt concentrations. Wild type FGF1 is known to elute off of
heparin-Sepharose at 1500mM NaCl because at this strength of NaCl, FGF1’s
electrostatic interactions with heparin-Sepharose would completely break apart to release
the bound FGF1 from the resin. SDS-PAGE analysis shows that like the wild type FGF1,
G134E also eluted from the column at 1500mM NaCl concentration. Collecting the
G134E at a 1500mM NaCl salt concentration, serves as conformation that the G134E
mutation does not significantly alter FGF1 surface residues and its inherent affinity to
heparin. Overexpression and purification of G134E-FGF1 was analyzed by SDS-PAGE
analysis.
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Figure 9: SDS-PAGE analysis of G134E-FGF1 purification fractions collected from heparin-Sepharose column: Lane-1:
Protein marker, Lane-2: insoluble cell debris, Lane-3: clear cell lysate, Lane-4: flow-through of 100mM NaCl 10mM
phosphate buffer, Lane-5: 500mM NaCl 10mM phosphate buffer, Lane-6: 800mM NaCl 10mM phosphate buffer, Lane7: 1500mM NaCl 10mM phosphate buffer, Lane-8: 8M Urea wash to clean the column. The bottom band, boxed in red
in lane-7 corresponding to 16kD position, confirms the presence of G134E FGF-1. The band in lane-7 at the 30kD
position is the result of two possibilities: a G134E dimer or a TCA artifact.

Determination of heparin binding affinity G134E-FGF1 mutant using isothermal titration
calorimetry:
ITC was used to measure the dissociation constant (Kd) of heparin to the wild type
FGF-1 and to the G134E mutant. Both the G134E-FGF1 mutant and the wild-type
dissociation constants were calculated. A higher Kd is indicative of a weaker interaction
and less affinity between two molecules, in our case heparin and FGF1, where a lower Kd
signifies a tighter binding interaction between two molecules. Compared to the wild type
FGF1, G134E-FGF1 had a higher Kd (wild type FGF1’s Kd = 0.316 µM; G134E-FGF1’s
Kd = 6.67 µM) which corresponds to G134E having a moderately decreased affinity to
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heparin which is in agreement with the hypothesis of introduction of negative charge in
the heparin interaction region results in decreased binding affinity.
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Figure 10: Isothermograms of wild type FGF1 (left) and G134E mutant (right) showing their respective
interaction to heparin. The bottom panel represents the best-fit of the raw data using one-set of sites
binding model available from Origin software. Dissociation constants (Kd ) of 6.67 μM (G134E) and 0.316
μM (wtFGF1) were calculated.

Determination of stability of G134E-FGF1by limited proteolytic digestion assay:
To assess G134E-FGF1’s resistance to proteolytic cleavage, G134E was subjected
to limited trypsin digestion followed by SDS-PAGE analysis and densitometric scanning.
By comparing the assays of G134E-FGF1 to that of wtFGF1, we may assess the affects
that this point mutation has on the resistance to proteolytic degradation of FGF1. Trypsin
was our protease of choice because it is not a specialized protease limited by consensus
sequences. Rather, trypsin cleaves with general selectivity at the carboxyl end of lysine
and arginine residues. This generalized cleavage of trypsin allows us to achieve a more

29

uniform proteolytic activity over time which is useful to characterize the intrinsic
structural stability and resistance to proteolytic degradation of the G134E mutant.

Figure 11: SDS PAGE analyses of the limited trypsin digestion products of the G134E mutant compared to that of wild
type FGF1 in the presence and absence of heparin. Lane-1 corresponds to the time zero sample before trypsin addition.
Each subsequent lane (lanes 2-10) represent a 100 µL extraction from the trypsin reaction collected and then halted
via addition of trichloroacetic acid (TCA) at 5 minute intervals, with lane 10 concluding the assay at 45 minutes. Lane1: time-zero sample, Lane-2: 5 minutes, Lane-3: 10 minutes, Lane-4: 15 minutes, Lane-5: 20 minutes, Lane-6: 25
minutes, Lane-7: 30 minutes, Lane-8: 35 minutes, Lane-9: 40 minutes.
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Figure 12: Densitometric scan of the undigested wtFGF1 and G134E over time in the presence and absence of heparin
after treatment of trypsin. Lines of best fit are plotted through each data set. The data sets are represented as follows:
wtFGF1 (dark blue) in the presence of heparin; G134E-FGF1 (light blue) in the presence of heparin; G134E-FGF1 only
(orange), without heparin; and wtFGF1 only (green) in the absence of heparin.

Both the wild type FGF1 and G134E’s with-heparin plots are relatively stabilized
by the presence of heparin. This lends support to heparin acting as a shield to proteolytic
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degradation. Though wtFGF1 in the absence of heparin shows increased proteolytic
degradation compared to when it is bound to heparin, the G134E mutant is characterized
with a substantial rate of digestion—over 90% of the G134E only mutant was degraded
after 20 minutes of trypsin exposure in the absence of heparin whereas approximately
20% of the wild type FGF-1 protein was cleaved. This data shows that G134E-FGF1
without heparin is highly susceptible to trypsin degradation compared to that of the wild
type. The increased susceptibility of the G134E mutation could be the result of the
introduction of a negatively charged amino acid causing the protein core to be less tightly
packed. An unpacked core would allow for trypsin to act upon more of its lysine and
arginine targets consequently causing a greater digestion rate.

Ascertaining surface hydrophobicity of G134E-FGF1 mutant:
ANS titration was performed to assess the surface hydrophobic differences between the
G134E mutant and wild type FGF1. By measuring the fluorescence of bound ANS to the
exposed hydrophobic pockets the folding and flexibility of G134E can be compared to
wtFGF1. ANS is a fluorescent, hydrophobic dye that gives a signal when it binds to
exposed hydrophobic pockets on the surface of protein (Zorrilla et al. 2010). Specifically,
ANS lends information of a mutant proteins’ susceptibility to aggregation by a greater
fluorescence emission denoting a movement of hydrophobic residues from the
hydrophobic interior of the protein to the hydrophilic exterior.
Comparisons between the global structure of G134E and wtFGF1 can be assessed
by comparing the ANS data. The data reveals that when increasing the ANS
concentrations both wtFGF1 and G134E mutant follows the same trend both with and
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without heparin. This indicates that the G134E mutant core is packed in a similar fashion
to the wild type. Therefore, a similar amount of hydrophobic residues are exposed
between G134E and wtFGF1. This data also indicates that the folding and flexibility of
G134E-FGF1 is similar to that of the wild type. Additionally, this data suggests that the
G134E appears to render the protein more prone to aggregation.
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Figure 13: ANS titration of wild type FGF1 and G134E mutant in the presence and absence of heparin.
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Determining the changes in the secondary structure of G134E-FGF1 mutant:
The hallmark CD spectra of a β-sheet is known to be positive from 190nm to
approximately 210 nm then negative for the remainder of the plot. However, because
FGF1 is arranged in a β-barrel (more precisely, a β-trefoil fold), the dipoles of the βsheets are cancelled. Consequently, the CD spectra of a β-barrel is different from that of a
β-sheet where the far UV CD plot for a β-barrel has a strong positive peak at 228nm—
indicative of a β-barrel. Using polarized light, the secondary structure of G134E is
analyzed compared to wtFGF1 with and without the presence of heparin. Because the
peak of 228 is clearly visible for the mutant plots, both with and without heparin, the CD
assay reveals that the G134E mutation does not perturb secondary structure and the βbarrel of FGF1 is left intact; therefore, secondary structure for G134E is upheld and
similar to that of the wild type.
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Figure 14: Overlay
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the presence and
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Figure 15: Thermal denaturation profile of the wild type and G134E mutant of FGF1 in the presence and absence of
heparin monitored by 228 nm molar ellipticity.

Because the β-barrel is observable at 228nm, thermal denaturation was observed at a
wavelength of 228nm to assess the thermal stability of the β-barrel consequently yielding
the thermal stability of the entire protein. Both thermal denaturation temperatures of wild
type FGF1 and G134E were measured by finding the average value of molar ellipticity
values then corresponding the average molar ellipticity to a temperature. The
denaturation temperature of wild type FGF1 was measured to be 49 oC where G134E’s
thermal denaturation temperate was 41 oC. The lower melting temperature (Tm) of the
G134E mutant is describing that G134E loses local integrity of secondary structure at a
lower temperature. Although the G134E does not perturb the global secondary structure
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and the β-barrel is upheld, the G134E mutant is thermodynamically less stable than the
wild type and G134E denatures at a lower temperature which is consistent with the
trypsin digestion data.

Determination of changes in tertiary structure of G134E-FGF1 using intrinsic
fluorescence as a probe:
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Figure 16: Overlay of intrinsic fluorescence spectra of wild type FGF1 and G134E mutant in the presence and absence
of heparin.

To understand changes in the tertiary structure of the G134E mutant compared to that of
the wild type in the presence and absence of heparin intrinsic fluorescence measurement
was performed. The peak for all data sets at approximately 308nm is indicative of
tyrosine fluorescence, a signature pattern for FGF1. The intrinsic fluorescence spectra
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reveals that the G134E mutant induces a solvent exposed tryptophan in both the presence
and absence of heparin due to the shouldering of the G134E plots at 350nm.

Effect of G134E mutation on the biological activity of FGF1:
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Figure 17: Cell proliferation activity of the wild type FGF1 and G134E mutation with heparin (bottom graph) and
without heparin (top graph).
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In both the presence and absence of heparin the G134E mutation has similar cell
proliferation rates as the wild type. In the presence of heparin, G134E causes just slightly
more or equal cell proliferation at almost all concentrations. In the absence of heparin,
G134E causes slightly more cell proliferation than the wild type up until 0.6nM
concentration.

Conclusions and Future Work:
The biophysical characterization showed that the G134E-FGF1 mutant induces
minor yet noteworthy changes to the human acidic FGF1. ITC results showed that G134E
mutation resulted in decreased binding affinity to heparin with a higher dissociation
constant (Kd) compared to the wild type. Although G134E’s innate propensity to heparin
was moderately reduced, G134E-FGF1 still strongly associates with heparin. This was
proven by successful purifications of G134E where 1500mM NaCl was required to
disrupt the interaction between G134E-FGF1 and heparin. Limited trypsin digestion of
G134E suggests that introduction of a negative charge in the heparin binding pocket
renders heparin to not efficiently confer additional resistance against trypsin digestion.
Although CD data supports that secondary structure of G134E is not
compromised and the β-barrel is still intact, the introduction of negatively charged
glutamic acid appears to increases the conformational flexibility as compared to the wild
type FGF1. This inference is supported by intrinsic fluorescence and thermal denaturation
wherein the β-barrel structure of the G134E mutant is observed to be disrupted at a lower
temperature than the wild type FGF1. In addition, results of the ANS binding
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experiments suggest that the G135E mutation appears to render the protein more prone to
aggregation than the wild type FGF1. The evidence supports that the structural integrity
of G134E is well preserved but minor structural perturbation induced by the introduction
of the negatively charged glutamic acid causes the protein to be marginally less
thermodynamically stable.
Interestingly, the induced structural changes, caused due to the mutation, do not
appear to alter the mitogenic activity of the growth factor.
In regard to future work, the Kumar lab will carry out multidimensional NMR
spectroscopy experiments which are likely to provide atomic level information of the
subtle conformational changes caused by the G135E mutation. Further studies to
determine G134E’s affinity towards varying FGFRs isoforms using ITC experimentation
will provide information on the binding affinity between the mutant protein and the
receptor.
The results of this study are likely to aid future studies, utilizing point mutations
of FGF1, to understand and characterize the residues that impact the stability of FGF1. In
particular, the results of this study provide interesting leads in understanding the
structural forces responsible for the FGF-heparin interaction
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